This position paper presents facts and figures regarding the evolution of interactions between pharma companies and physicians, and makes practical recommendations to ensure regular and impactful interactions in the years to come
News
With 3 million people affected in France, rare diseases are a major public health issue. 25% of...
This position paper covers the following key issues:
French health authorities intent – cautiously – to facilitate the development of the biosimilars market by: This...